About Us

Supriya Lifescience Limited headquartered in Mumbai, India is a public listed generic pharmaceutical company established in 1987 dedicated to developing, commercializing APIs & FDFs to treat patients with various diseases and infections. The API facility located at Lote, Maharashtra, India is multiple times USFDA, EDQM/EUGMP approved, and Health Canada approved.

Read More Watch Video

Area of Focus

API

FDF

CDMO
40+

Products

86+

Countries

1500+

Customers

22%

& above CAGR since 2019

400+

Employee Strength

We have a global footprint that extends across 86 countries

APIs

FDF

Awards

Latest News

21 March 2025

Supriya Lifescience Powers Ahead With New 5 MWp Solar Facility

Read More

20 March 2025

Supriya Lifescience Powers Ahead With A New 5 MWp Solar Facility

Read More

20 March 2025

Supriya Lifescience Launches 5 MWp Solar Power Plant to Boost Sustainability Efforts

Read More

19 March 2025

Supriya Lifescience expands solar power capacity with 5 MWp facility in Maharashtra

Read More

19 March 2025

Supriya Lifescience expands with new 5 MWp solar power plant

Read More

18 March 2025

Supriya Lifescience Powers Ahead with a New 5 MWp Solar Facility

Read More

17 March 2025

Supriya Lifescience Powers Ahead With New 5 MWp Solar Facility

Read More

08 March 2025

Breaking Barriers: Empowering Women For A $5 Trillion Economy Ms. Shivani Wagh, Joint Managing Director, Supriya Lifescience Ltd.

Read More

08 March 2025

Women are smashing stereotypes-But when will the stigma croak?

Read More

26 February 2025

In conversation with Krishna Raghunathan, CFO of Supriya Lifescience Ltd

Read More

28 January 2025

Supriya Lifescience Q3 FY25 PAT Jumps 57% YoY to Rs 46.78 Crore

Read More

28 January 2025

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

Read More

27 January 2025

Supriya Lifesci Standalone December 2024 Net Sales at Rs 185.65 crore, up 32.54% Y-o-Y

Read More

27 January 2025

Supriya Lifescience Q3FY25 PAT Jumps 57% Yoy To Rs 46.78 Crore.

Read More

26 January 2025

Supriya Lifescience Third Quarter 2025 Earnings: EPS: ₹5.82 (vs ₹3.70 in 3Q 2024)

Read More

25 January 2025

Supriya Lifescience Q3FY25 PAT Jumps 125% YoY to Rs 46.78 Crore

Read More

25 January 2025

Supriya Life Sciences Q3 Results 2025 on 25 Jan, 2025: profit rise by 57.03% YOY, profit at ₹46.78 crore and revenue at ₹185.65 crore

Read More

25 January 2025

Supriya Lifescience Q3FY25 PAT Jumps 125% YoY to Rs 46.78 Crore

Read More

24 January 2025

Supriya Lifescience standalone net profit rises 57.03% in the December 2024 quarter

Read More

31 December 2024

Supriya Lifescience expects new capacities to drive growth

Read More

27 December 2024

Supriya Lifescience MD Saloni Wagh on adding capacity, topline target and more

Read More

Several awards for excellence and outstanding performance.

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. Facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India.

Read More
BSE
NSE